BLCO

Business Context and Reporting Period

Company: Bausch + Lomb Corporation (BLCO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: A leading global eye health company operating in three segments: Vision Care (contact lenses, OTC eye drops, vitamins), Pharmaceuticals (prescription eye medications), and Surgical (medical devices and equipment). The company is currently a subsidiary of Bausch Health Companies Inc. (BHC), which owns approximately 88.1% of outstanding shares. A full separation from BHC is planned but subject to debt leverage targets and regulatory approvals.

Key Financial Metrics (2024 vs. 2023)

Segment Performance:

• Pharmaceuticals: Revenue grew 45% to $1.209B, driven by the XIIDRA acquisition and MIEBO launch.
• Vision Care: Revenue grew 8% to $2.739B, driven by dry eye portfolio and contact lens volumes.
• Surgical: Revenue grew 10% to $843M, driven by consumables and premium IOLs.

Material Changes and Drivers

• Revenue Growth: Driven by a $348M increase in volumes, $293M from acquisitions (primarily XIIDRA and Blink), and $81M from net pricing increases. Growth was partially offset by a $69M unfavorable foreign currency impact.
• Net Loss Expansion: Despite a $32M increase in operating income, the net loss widened by $57M primarily due to a $116M increase in interest expense ($399M in 2024 vs. $283M in 2023) resulting from higher debt levels and interest rates.
• Acquisitions: Significant activity included the acquisition of XIIDRA (2023), Blink Product Line (2023), Trukera Medical (2024), and Elios Vision (2024). These contributed to revenue growth but also increased amortization and interest costs.
• Cost Structure: Selling, General, and Administrative (SG&A) expenses increased 20% to $2.082B, largely due to marketing spend for XIIDRA, MIEBO, and Lumify.

Outlook, Risks, and Management Commentary

• Separation from BHC: The company is exploring options to complete the separation, including a distribution of shares to BHC shareholders or a sale transaction. Completion is contingent on BHC achieving targeted debt leverage ratios and obtaining necessary approvals. There is no assurance the separation will occur on the anticipated timeline.
• Debt and Liquidity: The company carries significant debt ($4.84B principal) with a weighted average interest rate of 7.95%. It maintains a $500M revolving credit facility with $358M available. Management expects current liquidity to meet needs for the next 12 months.
• Key Risks:
  • Interest Rate Sensitivity: Variable rate debt exposes the company to rising interest costs.
  • Regulatory & IP: Risks include patent expirations (e.g., PreserVision), generic competition, and FDA/EMA regulatory hurdles for new products.
  • Geopolitical: Ongoing conflicts in Russia/Ukraine and the Middle East pose supply chain and revenue risks, though current exposure is limited (~3% of revenue from Russia/Ukraine/Belarus).
  • Supply Chain: Reliance on single-source suppliers for key products (e.g., Lumify, XIIDRA) creates vulnerability to disruptions.
• Guidance: The filing does not provide specific numerical guidance for 2025 revenue or earnings, citing uncertainties related to the separation, macroeconomic conditions, and interest rates.

Investor Verification Checklist

• Separation Timeline: Verify the status of BHC's debt leverage ratios and any updates on the distribution or sale transaction timeline.
• Debt Covenants: Confirm continued compliance with financial covenants (leverage and interest coverage ratios) given the high interest expense environment.
• Acquisition Integration: Monitor the commercial performance and integration of recent acquisitions (Elios Vision, Trukera Medical) against expectations.
• Patent Litigation: Track outcomes of ongoing IP litigation regarding Lumify and PreserVision, which could impact future revenue streams.
• Interest Rate Exposure: Assess the impact of potential further interest rate hikes on the company's variable-rate debt obligations.